Skip to main content

Advertisement

Open Peer Review Reports for: Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
15 May 2018 Submitted Original manuscript
18 Jul 2018 Reviewed Reviewer Report - Laura Bonanno
20 Oct 2018 Reviewed Reviewer Report - Maurizio MARTINI
4 Nov 2018 Author responded Author comments - YASUHIRO TSUTANI
Resubmission - Version 2
4 Nov 2018 Submitted Manuscript version 2
17 Nov 2018 Author responded Author comments - YASUHIRO TSUTANI
Resubmission - Version 3
17 Nov 2018 Submitted Manuscript version 3
21 Nov 2018 Author responded Author comments - YASUHIRO TSUTANI
Resubmission - Version 4
21 Nov 2018 Submitted Manuscript version 4
26 Nov 2018 Author responded Author comments - YASUHIRO TSUTANI
Resubmission - Version 5
26 Nov 2018 Submitted Manuscript version 5
Publishing
28 Nov 2018 Editorially accepted
10 Dec 2018 Article published 10.1186/s12885-018-5146-3

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement